| Autor: |
Matsumoto K; Department of Pharmacy, Yamanashi Prefectural Central Hospital., Morimoto Y; Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University., Wakatsuki J; Department of Pharmacy, Yamanashi Prefectural Central Hospital., Sakuma D; Department of Pharmacy, Yamanashi Prefectural Central Hospital., Mukouyama K; Department of Nursing, Yamanashi Prefectural Central Hospital., Inoue M; Department of Breast Surgery, Yamanashi Prefectural Central Hospital., Kimura A; Department of Breast Surgery, Yamanashi Prefectural Central Hospital., Hirosawa I; Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University., Watanabe K; Education and Research Center for Clinical Pharmacy, Showa Pharmaceutical University. |
| Jazyk: |
angličtina |
| Zdroj: |
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan [Yakugaku Zasshi] 2024; Vol. 144 (6), pp. 685-690. |
| DOI: |
10.1248/yakushi.23-00206 |
| Abstrakt: |
Docetaxel (DTX) is a key drug used in perioperative chemotherapy for breast cancer. Edema is a known adverse effect of DTX, but its effect on health-related QOL (HRQOL) is unclear. In this study, we evaluated the effects of edema caused by administration of DTX on HRQOL in patients with early-stage breast cancer. We prospectively investigated patients diagnosed with early-stage breast cancer (stage I-III) who received 4 cycles of DTX as preoperative or postoperative chemotherapy between September 2021 and December 2022 at Yamanashi Prefectural Central Hospital. The circumference of each extremity was measured at each administration of DTX, and limb edema was evaluated by Common Terminology Criteria for Adverse Events version 5.0. HRQOL was evaluated using SF-12 version 2, which has a range of 0-100 (national standard, 50), and compared between the presence and absence of grade 2 or higher edema and between before and after administration of DTX. Twenty patients met the eligibility criteria and were included in the study. There was no difference in the HRQOL score according to whether grade 2 limb edema was present. The median HRQOL summary scores before and after administration of DTX were 51.1 and 50.8 (p=0.763), respectively, for mental health, 52.6 and 49.4 (p=0.005) for physical health, and 38.9 and 37.5 (p=1.000) for role/social health. We found no direct effect of DTX-induced limb edema on HRQOL in patients with early-stage breast cancer. However, HRQOL summary scores indicated that administration of DTX reduced physical health in these patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
